Drugs / DIAG723
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07623525 | Jun 2026 → Nov 2027 expected | hereditary hemorrhagic telangiectasia, pulmonary arterial hypertension | Diagonal Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DIAG723 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07623525 ↗ |
| Action | Activate | “a bispecific agonist monoclonal antibody targeting activin receptor-like kinase 1 (ALK-1) and bone morphogenetic protein receptor type II (BMPRII)” NCT07623525 ↗ |
| Modality | Monoclonal antibody | “a bispecific agonist monoclonal antibody targeting activin receptor-like kinase 1 (ALK-1) and bone morphogenetic protein receptor type II (BMPRII)” NCT07623525 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT07623525 ↗ |